Word

CRESCENDO BIOLOGICS

Status

Registered

Status Code

700

Status Date

Tuesday, June 12, 2018

Serial Number

79209645

Registration Number

5488713

Registration Date

Tuesday, June 12, 2018

Mark Type

3000

Filing Date

Friday, October 21, 2016

Published for Opposition

Tuesday, March 27, 2018

Trademark Owner History

Crescendo Biologics Limited - Original Registrant

Classifications

40 Treatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments

5 Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products

1 Chemicals used in industry and science; chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products

The mark consists of a design of three circles each having U-shaped cut-outs. The three circles are centered above the stylized wording "Crescendo" directly above the stylised wording "biologics".
Color is not claimed as a feature of the mark.
"BIOLOGICS"

Trademark Events

Oct 27, 2023

Limitation From The Ib Examined, No Action Is Needed

Aug 19, 2023

Restriction Of Holder's Right Of Disposal Received

Jun 12, 2023

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Oct 6, 2018

Final Decision Transaction Processed By Ib

Sep 18, 2018

Final Disposition Notice Sent To Ib

Sep 18, 2018

Final Disposition Processed

Sep 12, 2018

Final Disposition Notice Created, To Be Sent To Ib

Jun 12, 2018

Registered-Principal Register

Mar 27, 2018

Official Gazette Publication Confirmation E-Mailed

Mar 27, 2018

Published For Opposition

Mar 24, 2018

Notification Processed By Ib

Mar 7, 2018

Notification Of Possible Opposition Sent To Ib

Mar 7, 2018

Notification Of Notice Of Publication E-Mailed

Mar 7, 2018

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Feb 16, 2018

Approved For Pub - Principal Register

Feb 14, 2018

Teas/Email Correspondence Entered

Feb 14, 2018

Correspondence Received In Law Office

Feb 14, 2018

Teas Request For Reconsideration Received

Feb 1, 2018

Attorney/Dom.Rep.Revoked And/Or Appointed

Feb 1, 2018

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Jan 12, 2018

Final Refusal Mailed

Jan 11, 2018

Final Refusal Written

Dec 20, 2017

Teas/Email Correspondence Entered

Dec 19, 2017

Correspondence Received In Law Office

Dec 19, 2017

Teas Response To Office Action Received

Dec 7, 2017

New Representative At Ib Received

Jul 14, 2017

Refusal Processed By Ib

Jun 23, 2017

Non-Final Action Mailed - Refusal Sent To Ib

Jun 23, 2017

Refusal Processed By Mpu

Jun 16, 2017

Application Filing Receipt Mailed

Jun 15, 2017

Non-Final Action (Ib Refusal) Prepared For Review

Jun 14, 2017

Non-Final Action Written

Jun 12, 2017

Assigned To Examiner

Jun 12, 2017

New Application Office Supplied Data Entered

Jun 8, 2017

Sn Assigned For Sect 66a Appl From Ib